EY to bring tailored AI solutions via Integrated Solutions portfolio; KPMG hails AIUC-1 certification for AI; April announces ...
An in vivo small-molecule drug screen in developing zebrafish larvae identifies dozens of unique chemical modulators capable of reducing atherogenic apolipoprotein B levels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results